New hope for brain cancer? experimental combo tested in early trial
NCT ID NCT03587038
First seen Dec 10, 2025 · Last updated May 12, 2026 · Updated 20 times
Summary
This early-stage study tested whether adding an experimental drug called OKN-007 to standard chemotherapy and radiation is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. About 27 adults who had surgery for their tumor took part. The main goal was to find the highest safe dose and note any side effects. This is not a cure, but aims to improve control of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73117, United States
Conditions
Explore the condition pages connected to this study.